Drug - Jakafi (ruxolitinib) [Incyte Corp.]
June 2012
Therapeutic area - myelofibrosis
Patient has documented diagnosis of intermediate or high-risk myelofibrosis.
Initial authorization will be approved for 6 months.
Subsequent authorization requires documentation of spleen size reduction or symptomatic improvement.
Jakafi is a kinase inhibitor indicated for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. It is recommended, in the label, that Jakafi be discontinued if, after 6 months, there is no spleen reduction or symptom improvement.
MHCP Provider Call Center 651-431-2700 or 800-366-5411
